Optogenetic Central Amygdala Stimulation is Highly Reinforcing and Strongly Outcompetes Fentanyl Self-Administration in Male, but not Female, Rats

Kavli Affiliate: Patricia Janak

| Authors: Emma Chaloux-Pinette, Maricela Vela Mirelez-Prince, Samantha Soto, Kirtana Ananth, Xiao Tong, Vanessa Silva, Daniela Rodriguez and Patricia H Janak

| Summary:

The central nucleus of the amygdala plays a key role in many aspects of substance use disorders, in particular biasing behaviors toward one drug or natural reward over another, yet the role of this region in opioid self-administration remains unclear. Here, we report that pharmacological inactivation of the central amygdala reduces fentanyl self-administration, while intra-central amygdala opioid receptor antagonism dose-dependently increases fentanyl self-administration. We tested whether optogenetic activation of the central amygdala would increase motivation for fentanyl in rats with a long fentanyl self-administration history. While pairing fentanyl delivery with optogenetic central amygdala activation increased fentanyl self-administration, optoactivation itself was highly reinforcing and, in choice settings, was pursued over fentanyl despite mounting effort requirements, delays, and sporadic reward availability. Of note, under free response conditions, these effects were limited to male rats; while female rats avidly responded for optogenetic activation of the central amygdala, this activation was less effective in enhancing fentanyl intake, and it was not preferred over fentanyl. In contrast, under discrete trial choice which precluded independent regulation of intake of the two options, both females and males preferred optoactivation to fentanyl. These results demonstrate that optogenetic stimulation of neural activity within the anterior central amygdala does not appear to potentiate the reinforcing effects of fentanyl, but is itself highly reinforcing regardless of sex, and, in male rats can robustly outcompete fentanyl. In contrast, in females, fentanyl intake is relatively insensitive to competing opportunities for optoactivation, except when opportunities to obtain drug or optoactivation are sparse.

Read More